• Karyopharm flagged new Phase 3 SENTRY trial findings on selinexor with ruxolitinib in myelofibrosis, scheduled for presentation at EHA 2026.
• The analysis points to faster, deeper, sustained spleen shrinkage with similar symptom relief versus control.
• Data also suggest a potential survival benefit, with spleen response emerging as a predictor of overall survival in a post-hoc Phase 1 review.
• The company described the safety profile as manageable, supporting continued development of the combination in earlier-line patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Karyopharm Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606021002PR_NEWS_USPR_____NE72804) on June 02, 2026, and is solely responsible for the information contained therein.